as 11-07-2024 4:00pm EST
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | DURHAM |
Market Cap: | 679.3M | IPO Year: | N/A |
Target Price: | $11.50 | AVG Volume (30 days): | 3.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.29 | EPS Growth: | N/A |
52 Week Low/High: | $2.08 - $9.97 | Next Earning Date: | 11-08-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 4615.69% |
HUMA Breaking Stock News: Dive into HUMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
GlobeNewswire
11 days ago
Simply Wall St.
14 days ago
GlobeNewswire
16 days ago
The Wall Street Journal
23 days ago
GlobeNewswire
a month ago
TipRanks
a month ago
GlobeNewswire
a month ago
The information presented on this page, "HUMA Humacyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.